Cholangiocarcinoma epidemiology and demographics

Jump to navigation Jump to search

Xyz Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Xyz from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cholangiocarcinoma epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cholangiocarcinoma epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cholangiocarcinoma epidemiology and demographics

CDC on Cholangiocarcinoma epidemiology and demographics

Cholangiocarcinoma epidemiology and demographics in the news

Blogs on Cholangiocarcinoma epidemiology and demographics

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Cholangiocarcinoma epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Farima Kahe M.D. [2] Suveenkrishna Pothuru, M.B,B.S. [3]

Overview

Epidemiology and Demographics

Incidence

  • The incidence of cholangiocarcinoma is approximately 1-2 per 100,000 individuals in the United States.
  • The highest annual incidences of cholangiocarcinoma is 5.5 cases per 100,000 people in Japan, and 7.3 cases per 100,000 people in Israel.

Prevalence

  • The prevalence of cholangiocarcinoma is approximately 0.01% to 0.46% per 100,000 individuals.
  • The prevalence of cholangiocarcinoma in patients with primary sclerosing cholangitis may be as high as 30%, based on autopsy studies.

Case-fatality rate/Mortality rate

  • The mortality rate for intrahepatic cholangiocarcinoma among men increased from 0.17 to 0.78 per 100,000 in period of 1975-1979 to 1993-1997.
  • The mortality rate for intrahepatic cholangiocarcinoma among women women increased from 0.12 to 0.57 per 100,000 in period of 1975-1979 to 1993-1997.

Age

  • Patients of all age groups may develop cholangiocarcinoma.
  • The median age at the time of cholangiocarcinoma diagnosis is 70-80 years, except in patients with bile duct cystic disorders.
  • Bile duct cystic disorders usually develop cholangiocarcinoma much earlier, between 30 and 40 years.

Race

  • Cholangiocarcinoma usually affects individuals of the American Indian, Alaska Natives and Asian and Pacific Islanders race.

Gender

  • Cholangiocarcinoma is more common in males than in females.

Region

  • The majority of cholangiocarcinoma cases are reported in North America, Asia, and Australia.[1]

References

  1. McLean L, Patel T (2006). "Racial and ethnic variations in the epidemiology of intrahepatic cholangiocarcinoma in the United States". Liver Int. 26 (9): 1047–53. doi:10.1111/j.1478-3231.2006.01350.x. PMID 17032404.

Template:WH Template:WS